©The Author(s) 2026.
World J Gastrointest Oncol. Jan 15, 2026; 18(1): 113440
Published online Jan 15, 2026. doi: 10.4251/wjgo.v18.i1.113440
Published online Jan 15, 2026. doi: 10.4251/wjgo.v18.i1.113440
Table 2 Treatment-related characteristics of participants, n (%)
| Treatment-related characteristics | Total number of cases (n = 126) | CMT group (n = 87) | CMT + ICI group (n = 39) | χ² value | P value |
| Chemotherapy regimen | 0.852 | 0.653 | |||
| Taxane-based ± platinum | 75 (59.5) | 49 (56.3) | 26 (66.7) | ||
| Fluoropyrimidine ± platinum | 31 (24.6) | 23 (26.4) | 8 (20.5) | ||
| Other | 20 (15.9) | 15 (17.3) | 5 (12.8) | ||
| Chemotherapy cycle | 0.081 | 0.776 | |||
| ≥ 4 | 105 (83.3) | 72 (82.8) | 33 (84.6) | ||
| < 4 | 21 (16.7) | 15 (17.2) | 6 (15.4) | ||
| Immunotherapy cycle | 120.395 | < 0.001a | |||
| ≥ 4 | 38 (30.2) | 0 (0.0) | 38 (97.4) | ||
| < 4 | 88 (69.8) | 87 (100.0) | 1 (2.6) | ||
| Liver local treatment | 0.746 | 0.388 | |||
| Yes | 39 (31.0) | 29 (33.3) | 10 (25.6) | ||
| No | 87 (69.0) | 58 (66.7) | 29 (74.4) | ||
| Local treatment modalities | 2.626 | 0.662 | |||
| None | 87 (69.0) | 58 (66.7) | 29 (74.4) | ||
| Ablation | 24 (19.0) | 18 (20.7) | 6 (15.4) | ||
| Surgery | 4 (3.2) | 3 (3.4) | 1 (2.6) | ||
| TACE | 4 (3.2) | 4 (4.6) | 0 (0.0) | ||
| Radiotherapy | 7 (5.6) | 4 (4.6) | 3 (7.7) |
- Citation: Dai EH, Que SH, Xu H, Zhong GQ, Zhang Z, Liang X, Zhai SW, Li YT, Wang JJ, Feng W. Efficacy and safety of immune checkpoint inhibitors plus chemotherapy in esophageal cancer patients with liver metastases. World J Gastrointest Oncol 2026; 18(1): 113440
- URL: https://www.wjgnet.com/1948-5204/full/v18/i1/113440.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v18.i1.113440